ABSTRACT
PURPOSE: The aim of this study is to characterize the concentration-time profile, pharmacokinetics parameters, and therapeutic target attainment of meropenem in pediatric post-liver transplant patients according to the duration of infusion. METHODS: This is a prospective cohort of pediatric transplant recipients with preserved renal function receiving meropenem 40 mg/kg every 8 hours. The patients were stratified into 2 groups based on infusion duration: G1 (15 minutes of intermittent infusion) and G1 (3 hours of extended infusion). Two blood samples per child were collected during the same interval within 48 hours of starting the antimicrobial. Meropenem concentrations were determined by high-performance liquid chromatography with tandem mass spectrometry. Pharmacokinetic parameters were assessed using a noncompartmental analysis. The therapeutic target was defined as 100% of the time above the minimum inhibitory concentration. FINDINGS: Fourteen patients with 28 measured meropenem concentrations were included. Lower values of volume of distribution and meropenem clearance compared with other critically ill pediatric populations were found. All patients achieved the therapeutic target against gram-negative pathogens with a minimum inhibitory concentration of ≤8 mg/L. Patients receiving a 15-minute infusion had higher values of peak and trough concentrations, resulting in unnecessary increased total drug exposure when compared to patients receiving a 3-hour infusion (P < .05). CONCLUSIONS: Meropenem at 120 mg/kg/d attained the therapeutic target against sensitive microorganisms in pediatric liver transplant recipients. The extended infusion should be preferred for patient safety. Because of the pharmacokinetic changes resulting from liver transplantation, individualized meropenem dosing regimens may be necessary.
Subject(s)
Anti-Bacterial Agents , Liver Transplantation , Humans , Child , Meropenem , Anti-Bacterial Agents/therapeutic use , Liver Transplantation/adverse effects , Thienamycins/therapeutic use , Prospective Studies , Infusions, Intravenous , Critical Illness/therapy , Microbial Sensitivity TestsABSTRACT
BACKGROUND: The standard meropenem (MEPM) regimen allowed by insurance in Japan is 0.5 g two or three times a day. Differences in dosages and administration schedules in Japan were evaluated. METHODS: Patients with bacteremia for whom MEPM was used as the initial treatment at our institution between 2016 and 2021 were included. We retrospectively investigated patients classified into two groups: those treated according to severe infections (high-dose groupand others (low-dose group). After propensity score matching, we compared the probability of achieving free drug blood levels above the minimum inhibitory concentration (MIC) in 24 h (%fT > MIC) and outcomes. RESULTS: The probability of 100% fT > MIC was significantly higher in the high-dose group (96.4% vs 74.5%, odds ratio [OR] = 0.3, 95% confidence interval [CI] = 0.2-0.4, P = < 0.001). Regarding outcomes, the 30-day mortality rate was significantly lower in the high-dose group (1.4% vs. 11.4%, OR = 8.0, 95% CI = 1.5-43.7, P = 0.019). CONCLUSIONS: To improve outcomes in patients with bacteremia treated with MEPM, support for appropriate antimicrobial use is necessary for compliance with the dosage and administration schedule according to severe infections in initial treatment.
Subject(s)
Anti-Infective Agents , Bacteremia , Humans , Meropenem , Anti-Bacterial Agents/pharmacology , Retrospective Studies , Bacteremia/drug therapy , Microbial Sensitivity Tests , Thienamycins/therapeutic useABSTRACT
OBJECTIVE: To assess the activities of biapenem against multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis. METHODS: Biapenem/clavulanate (BP/CL) was evaluated for in vitro activity against Mycobacterium tuberculosis (Mtb) multidrug-resistant (MDR) isolates, extensively drug-resistant (XDR) isolates, and the H37RV strain. BP/CL activity against the H37Rv strain was assessed in liquid cultures, in macrophages, and in mice.. RESULTS: BP/CL exhibited activity against MDR and XDR Mtb isolates in liquid cultures. BP/CL treatment significantly reduced the number of colony forming units (CFU) of Mtb within macrophages compared with control untreated infected macrophages. Notably, BP/CL synergized in pairwise combinations with protionamide, aminosalicylate, and capreomycin to achieve a fractional inhibitory concentration for each pairing of 0.375 in vitro. In a mouse tuberculosis infection model, the efficacy of a cocktail of levofloxacin + pyrazinamide + protionamide + aminosalicylate against Mtb increased when the cocktail was combined with BP/CL, achieving efficacy similar to that of the positive control treatment (isoniazid + rifampin + pyrazinamide) after 2 months of treatment. CONCLUSION: BP/CL may provide a new option to clinically treat MDR tuberculosis.
Subject(s)
Anti-Infective Agents/therapeutic use , Mycobacterium tuberculosis/drug effects , Thienamycins/therapeutic use , Tuberculosis, Multidrug-Resistant/drug therapy , Animals , Anti-Infective Agents/pharmacology , Cell Line , Drug Evaluation, Preclinical , Macrophages , Mice , Thienamycins/pharmacologySubject(s)
Anti-Bacterial Agents/therapeutic use , Thienamycins/therapeutic use , Urinary Tract Infections/drug therapy , Anti-Bacterial Agents/pharmacology , Drug Approval , Humans , Meropenem , Microbial Sensitivity Tests , Randomized Controlled Trials as Topic , Thienamycins/pharmacology , United States , United States Food and Drug Administration , Urinary Tract Infections/microbiologyABSTRACT
A total of 18,656 Enterobacteriaceae and 4,175 Pseudomonas aeruginosa were consecutively collected from 85 US hospitals and tested for susceptibility by broth microdilution methods in a central monitoring laboratory (JMI Laboratories). The antimicrobial susceptibility and frequency of key resistance phenotypes were assessed and stratified by infection type as follows: bloodstream (BSI; 3,434 isolates; 15.0%), pneumonia (6,439; 28.2%), skin and skin structure (SSSI; 4,134; 18.1%), intra-abdominal (IAI; 951; 4.2%), and urinary tract (UTI; 7,873; 34.5%). Ceftazidime-avibactam was active against 99.9% to 100.0% of Enterobacteriaceae and 97.0% (pneumonia) to 99.4% (UTI) of P. aeruginosa isolates. Susceptibility rates were consistently lower for ß-lactams, such as ceftazidime (82.3% vs. 87.1-90.8%), piperacillin-tazobactam (87.5% vs. 90.2-95.6%), and meropenem (96.8% vs. 98.4-99.4%) among Enterobacteriaceae from pneumonia compared to other infection types. Susceptibility to gentamicin was also generally lower among isolates from pneumonia, whereas susceptibility to levofloxacin and colistin were lowest among BSI and SSSI isolates, respectively. The occurrence of multidrug-resistance (MDR; 8.2% overall), extensively drug-resistance (XDR; 1.1% overall), and carbapenem-resistant Enterobacteriaceae (CRE; 1.3% overall) phenotypes were markedly higher among isolates from patients with pneumonia compared to other infection types. Among P. aeruginosa, susceptibility rates for ceftazidime, piperacillin-tazobactam, and gentamicin were lowest among isolates from pneumonia, whereas susceptibility to meropenem was similar among isolates from BSI, pneumonia, and IAI (77.3-77.9%), and susceptibility to levofloxacin was markedly lower among UTI isolates (67.1%). The frequencies of P. aeruginosa isolates with MDR and XDR phenotypes were highest among isolates from patients with pneumonia.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Drug Resistance, Multiple, Bacterial/drug effects , Enterobacteriaceae Infections/drug therapy , Enterobacteriaceae/drug effects , Pseudomonas Infections/drug therapy , Pseudomonas aeruginosa/drug effects , Azabicyclo Compounds/therapeutic use , Ceftazidime/therapeutic use , Colistin/therapeutic use , Cross Infection/drug therapy , Drug Combinations , Humans , Meropenem , Microbial Sensitivity Tests/methods , Penicillanic Acid/analogs & derivatives , Penicillanic Acid/therapeutic use , Piperacillin/therapeutic use , Piperacillin, Tazobactam Drug Combination , Thienamycins/therapeutic use , United StatesABSTRACT
Meropenem-vaborbactam is a carbapenem and ß-lactamase inhibitor combination that is newly indicated for the treatment of complicated urinary tract infections (cUTI), including adult pyelonephritis. Vaborbactam was developed due to emergence of carbapenem-resistant strains of Enterobacteriaceae. In a phase I trial, patients that received meropenem-vaborbactam 2-2 g intravenously over 3 h every 8 h, Cmax was 58.2 ± 10.8 µg/mL for meropenem and 59.0 ± 8.4 µg/mL for vaborbactam. AUC0-8 was 186 ± 33.6 µg ⢠h/mL for meropenem and 204 ± 34.6 µg ⢠h/mL for vaborbactam. Vss = 16.3 ± 2.6 L for meropenem and 17.6 ± 2.6 L for vaborbactam. Protein binding for vaborbactam averaged 33% in humans. Plasma clearance ranged from 10.42 ± 1.85 to 14.77 ± 2.84 L/h. One phase III trial evaluated efficacy for meropenem-vaborbactam 2-2 g intravenously every 8 h versus piperacillin-tazobactam 4-0.5 g intravenously every 8 h in complicated UTI. It found non-inferiority and statistical superiority for meropenem in overall success at the end of treatment primary end point. In another phase III trial evaluating efficacy in carbapenem-resistant Enterobacteriaceae (CRE) infections, meropenem-vaborbactam 2-2 g intravenously every 8 h was associated with decreased 28-day mortality and increased clinical cure compared with a best available therapy group.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Boronic Acids/therapeutic use , Carbapenem-Resistant Enterobacteriaceae/drug effects , Enterobacteriaceae Infections/drug therapy , Enterobacteriaceae Infections/microbiology , Thienamycins/therapeutic use , Animals , Anti-Bacterial Agents/pharmacology , Boronic Acids/pharmacology , Carbapenem-Resistant Enterobacteriaceae/physiology , Carbapenems/pharmacology , Carbapenems/therapeutic use , Clinical Trials as Topic , Enterobacteriaceae Infections/diagnosis , Humans , Meropenem , Microbial Sensitivity Tests , Thienamycins/pharmacology , Tissue Distribution , Treatment Outcome , Urinary Tract Infections/drug therapy , Urinary Tract Infections/microbiology , beta-Lactamase Inhibitors/pharmacology , beta-Lactamase Inhibitors/therapeutic useABSTRACT
We report an unusual presentation of pulmonary embolism (PE) where a 58-year-old man first developed symptoms of community-acquired pneumonia. Despite antibiotic therapy, he remained unwell with rising inflammatory markers, general malaise and persistent cough. He developed stony dull percussion and absent breath sounds to his left mid to lower zones. Serial chest x-rays showed progression from lobar consolidation to a large loculated left-sided pleural collection. CT chest showed left-sided lung abscess, empyema and bronchopleural fistulation. Incidentally, the scan revealed acute left-sided PE and its distribution corresponded with the location of the left lung abscess and empyema. The sequence of events likely started with PE leading to infarction, cavitation, abscess formation and bronchopleural fistulation. This patient was managed with a 6-month course of rivaroxaban. After completing 2 weeks of intravenous meropenem, he was converted to 4-week course of oral co-amoxiclav and metronidazole and attained full recovery.
Subject(s)
Abscess/diagnostic imaging , Anti-Bacterial Agents/therapeutic use , Bronchial Fistula/diagnostic imaging , Infarction/diagnostic imaging , Pleural Diseases/diagnostic imaging , Pneumonia/drug therapy , Pulmonary Embolism/diagnostic imaging , Radiography, Thoracic , Abscess/drug therapy , Abscess/pathology , Amoxicillin-Potassium Clavulanate Combination/therapeutic use , Bronchial Fistula/drug therapy , Bronchial Fistula/physiopathology , Disease Progression , Drug Therapy, Combination , Humans , Infarction/drug therapy , Infarction/physiopathology , Male , Meropenem , Metronidazole/therapeutic use , Middle Aged , Pleural Diseases/drug therapy , Pleural Diseases/physiopathology , Pneumonia/diagnostic imaging , Pneumonia/physiopathology , Pulmonary Embolism/drug therapy , Pulmonary Embolism/physiopathology , Rivaroxaban/therapeutic use , Thienamycins/therapeutic use , Treatment OutcomeABSTRACT
This case series explored the pharmacokinetic/pharmacodynamic (PK/PD) characteristics of meropenem (MEM) in adult cystic fibrosis (CF) patients hospitalized for a pulmonary exacerbation. From January 2015 to June 2016, all adult patients with cystic fibrosis (CF) and chronic pulmonary infection due to meropenem (MEM)-susceptible/intermediate Pseudomonas aeruginosa who received at least 48 h of MEM as an extended 3-hour infusion for treating a pulmonary exacerbation were enrolled. MEM plasma concentrations were determined by high-performance liquid chromatography. Six adult CF patients with a median age of 47 years were included in the study. MEM showed a high Vd (mean 45.98 L, standard deviation [SD] ±34.45). A minimal PK/PD target of 40% T > minimum inhibitory concentration (MIC) with respect to the MEM MIC of P. aeruginosa strains isolated from sputum during exacerbation was achieved in 5/6 patients (83%). MEM failed to achieve this target only in one patient, whose strain showed the highest MEM MIC in our cohort (8 mg/L). In all patients, MEM was well tolerated, and no adverse events were reported. In conclusion, high-dose, extended-infusion MEM during pulmonary exacerbation showed a high Vd in six adult CF patients with high median age, and was well tolerated.
Subject(s)
Cystic Fibrosis/drug therapy , Pseudomonas Infections/drug therapy , Thienamycins/pharmacokinetics , Thienamycins/therapeutic use , Adult , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/pharmacokinetics , Anti-Bacterial Agents/therapeutic use , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Resistance, Bacterial , Female , Humans , Male , Meropenem , Microbial Sensitivity Tests , Middle Aged , Pseudomonas Infections/blood , Pseudomonas aeruginosa/drug effects , Thienamycins/administration & dosage , Thienamycins/bloodABSTRACT
The efficacy of empirical non-carbapenem antibiotics for extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia (ESBL-B) is still inconclusive. We conducted a multicenter retrospective cohort study to evaluate the efficacy of empirical non-carbapenem antibiotics for treating ESBL-B. Electronic medical records of individuals who were diagnosed with ESBL-B were reviewed between January 2010 and December 2014 at four university hospitals in Korea. Patients were classified into non-carbapenem and carbapenem groups according to the empirical antibiotic regimen. Patients treated with appropriate empirical antibiotics and who subsequently received carbapenems as definitive therapy were included in the analysis. The inverse probability of treatment weights, a statistical method that adjusts baseline statistics by giving weights based on propensity score, was used. During the study period, 232 adequately treated patients with ESBL-B were included in the analysis: 49 patients in the non-carbapenem group and 183 in the carbapenem group. The baseline characteristics and severity of infection were similar after propensity score weighting. The 30-day mortality rates for the two groups were not statistically significantly different (non-carbapenems 6.3% and carbapenems 11.4%; P = 0.42). In a multivariate analysis, empirical treatment with non-carbapenem antibiotics was not associated with 30-day all-cause mortality (HR 1.02, 95% CI 0.99-1.06, P = 0.14). In a subgroup analysis, empirical treatment with piperacillin-tazobactam was also not associated with 30-day all-cause mortality (HR 1.21, 95% CI 0.37-4.00, P = 0.75). Appropriate non-carbapenems were not inferior to carbapenems as initial empirical therapy for ESBL-B.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Bacteremia/drug therapy , Carbapenem-Resistant Enterobacteriaceae/drug effects , Escherichia coli Infections/drug therapy , Klebsiella Infections/drug therapy , Propensity Score , Aged , Bacteremia/microbiology , Bacteremia/mortality , Carbapenem-Resistant Enterobacteriaceae/isolation & purification , Ciprofloxacin/therapeutic use , Escherichia coli/drug effects , Escherichia coli/isolation & purification , Escherichia coli Infections/microbiology , Female , Humans , Klebsiella Infections/microbiology , Klebsiella pneumoniae/drug effects , Klebsiella pneumoniae/isolation & purification , Male , Meropenem , Middle Aged , Penicillanic Acid/analogs & derivatives , Penicillanic Acid/therapeutic use , Piperacillin/therapeutic use , Piperacillin, Tazobactam Drug Combination , Retrospective Studies , Tertiary Care Centers , Thienamycins/therapeutic use , Treatment OutcomeABSTRACT
The aim of this study was to evaluate the in vitro activity of ceftolozane/tazobactam and comparator agents tested against Enterobacteriaceae and Pseudomonas aeruginosa isolates from patients in the Asia-Pacific (APAC) region with healthcare-associated infections. Ceftolozane/tazobactam is an antipseudomonal cephalosporin combined with a well-established ß-lactamase inhibitor. A total of 1963 Gram-negative organisms (489 P. aeruginosa and 1474 Enterobacteriaceae) were consecutively collected using a prevalence-based approach from 14 medical centres in the APAC region. Antimicrobial susceptibility testing was performed by broth microdilution method as described by the CLSI and the results were interpreted according to EUCAST and CLSI breakpoint criteria. Ceftolozane/tazobactam [MIC50/90, 0.25/4 µg/mL; 89.2/85.8% susceptible (CLSI/EUCAST)] and meropenem [MIC50/90, ≤0.06/≤0.06 µg/mL; 96.3/96.5% susceptible (CLSI/EUCAST)] were the most active compounds tested against Enterobacteriaceae. Isolates displayed susceptibility rates to other ß-lactam agents ranging from 85.8/81.0% for piperacillin/tazobactam to 74.4/72.7% for cefepime and 72.8/68.1% for ceftazidime using CLSI/EUCAST breakpoints. Among the Enterobacteriaceae isolates, 3.6% were carbapenem-resistant Enterobacteriaceae (CRE) and 25.6% exhibited an extended-spectrum ß-lactamase (ESBL) non-CRE phenotype. Ceftolozane/tazobactam showed good activity against ESBL non-CRE phenotype strains of Enterobacteriaceae (MIC50/90, 0.5/16 µg/mL), but not against isolates with a CRE phenotype (MIC50/90, >32/>32 µg/mL). Ceftolozane/tazobactam was the most potent (MIC50/90, 0.5/4 µg/mL) ß-lactam agent tested against P. aeruginosa isolates, inhibiting 90.8% at an MIC of ≤4 µg/mL. Pseudomonas aeruginosa exhibited high rates of susceptibility to amikacin [91.2/89.4% (CLSI/EUCAST)] and colistin [98.4/100.0% (CLSI/EUCAST)]. Ceftolozane/tazobactam was the most active ß-lactam agent tested against P. aeruginosa and demonstrated higher in vitro activity than available cephalosporins when tested against Enterobacteriaceae.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Cephalosporins/therapeutic use , Cross Infection/drug therapy , Enterobacteriaceae Infections/drug therapy , Enterobacteriaceae/drug effects , Epidemiological Monitoring , Penicillanic Acid/analogs & derivatives , Pseudomonas Infections/drug therapy , Pseudomonas aeruginosa/drug effects , beta-Lactamase Inhibitors/therapeutic use , Amikacin/therapeutic use , Asia, Southeastern , Colistin/therapeutic use , Cross Infection/microbiology , Drug Resistance, Multiple, Bacterial , Enterobacteriaceae/isolation & purification , Enterobacteriaceae Infections/microbiology , Humans , Meropenem , Microbial Sensitivity Tests , Penicillanic Acid/therapeutic use , Pseudomonas Infections/microbiology , Pseudomonas aeruginosa/isolation & purification , Tazobactam , Thienamycins/therapeutic useABSTRACT
Objective This study aimed to investigate the epidemiology and changes in antibacterial susceptibility of children in Shenmu City, northern Shaanxi, and provide a basis for rational drug use. Methods The distribution and drug resistance pattern of pathogenic bacteria isolated from children were retrospectively analysed. Results A total of 573 strains of pathogens were cultivated. A total of 201 (35.07%) strains of Gram-positive cocci and 183 (31.93%) strains of Gram-negative cocci were detected. A total of 189 (32.98%) strains of fungi were detected. The resistance rate of Staphylococcus to penicillin was 100% and that to erythromycin was 90.69%. There were varying degrees of resistance to other drugs, but no single strain had vancomycin resistance. Gram-negative bacilli were generally resistant to ampicillin, but had low resistance to the combined preparation of enzyme inhibitors, quinolones, and aminoglycosides, and were highly sensitive to imipenem and meropenem. Conclusion Gram-negative bacilli are the main pathogens of bacterial infection in the paediatric ward. Strengthening clinical monitoring of bacterial distribution in paediatric clinical isolates and understanding changes in drug resistance are important for guiding the rational use of antibiotics. These measures could also prevent emergence and spreading of resistant strains.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Drug Resistance, Multiple, Bacterial , Fungi/drug effects , Gram-Negative Bacteria/drug effects , Gram-Positive Cocci/drug effects , Ampicillin/therapeutic use , Antifungal Agents/therapeutic use , Child , Child, Preschool , Erythromycin/therapeutic use , Female , Fungi/growth & development , Fungi/isolation & purification , Gram-Negative Bacteria/growth & development , Gram-Negative Bacteria/isolation & purification , Gram-Negative Bacterial Infections/drug therapy , Gram-Negative Bacterial Infections/microbiology , Gram-Positive Bacterial Infections/drug therapy , Gram-Positive Bacterial Infections/microbiology , Gram-Positive Cocci/growth & development , Gram-Positive Cocci/isolation & purification , Humans , Imipenem/therapeutic use , Infant , Infant, Newborn , Male , Meropenem , Microbial Sensitivity Tests , Mycoses/drug therapy , Mycoses/microbiology , Penicillins/therapeutic use , Retrospective Studies , Thienamycins/therapeutic use , Vancomycin/therapeutic useABSTRACT
Emerging multidrug-resistant bacteria are a challenge for modern medicine, but how these pathogens are so successful is not fully understood. Robust antibacterial vaccines have prevented and reduced resistance suggesting a pivotal role for immunity in deterring antibiotic resistance. Here, we show the increased prevalence of Klebsiella pneumoniae lipopolysaccharide O2 serotype strains in all major drug resistance groups correlating with a paucity of anti-O2 antibodies in human B cell repertoires. We identify human monoclonal antibodies to O-antigens that are highly protective in mouse models of infection, even against heavily encapsulated strains. These antibodies, including a rare anti-O2 specific antibody, synergistically protect against drug-resistant strains in adjunctive therapy with meropenem, a standard-of-care antibiotic, confirming the importance of immune assistance in antibiotic therapy. These findings support an antibody-based immunotherapeutic strategy even for highly resistant K. pneumoniae infections, and underscore the effect humoral immunity has on evolving drug resistance.
Subject(s)
Antibodies, Bacterial/therapeutic use , Antibodies, Monoclonal/therapeutic use , Klebsiella Infections/therapy , Klebsiella pneumoniae/physiology , O Antigens/immunology , Animals , Anti-Bacterial Agents/therapeutic use , Antibodies, Bacterial/immunology , Antibodies, Monoclonal/immunology , Cell Line , Disease Models, Animal , Drug Resistance, Multiple, Bacterial/genetics , Drug Resistance, Multiple, Bacterial/immunology , Humans , Immunity, Humoral , Immunologic Factors/therapeutic use , Immunotherapy/methods , Klebsiella Infections/immunology , Klebsiella Infections/microbiology , Klebsiella Infections/mortality , Klebsiella pneumoniae/drug effects , Meropenem , Mice , Mice, Inbred C57BL , Microbial Sensitivity Tests , Serogroup , Survival Rate , Thienamycins/therapeutic useABSTRACT
BACKGROUND: Over recent decades, a dramatic increase in infections caused by multidrug-resistant pathogens has been observed worldwide. The aim of the present study was to investigate the relationship between local resistance bacterial patterns and antibiotic consumption in an intensive care unit in a Romanian university hospital. METHODS: A prospective study was conducted between 1st January 2012 and 31st December 2013. Data covering the consumption of antibacterial drugs and the incidence density for the main resistance phenotypes was collected on a monthly basis, and this data was aggregated quarterly. The relationship between the antibiotic consumption and resistance was investigated using cross-correlation, and four regression models were constructed, using the SPSS version 20.0 (IBM, Chicago, IL) and the R version 3.2.3 packages. RESULTS: During the period studied, the incidence of combined-resistant and carbapenem-resistant P. aeruginosa strains increased significantly [(gradient = 0.78, R2 = 0.707, p = 0.009) (gradient = 0.74, R2 = 0.666, p = 0.013) respectively], mirroring the increase in consumption of ß-lactam antibiotics with ß-lactamase inhibitors (piperacillin/tazobactam) and carbapenems (meropenem) [(gradient = 10.91, R2 = 0.698, p = 0.010) and (gradient = 14.63, R2 = 0.753, p = 0.005) respectively]. The highest cross-correlation coefficients for zero time lags were found between combined-resistant vs. penicillins consumption and carbapenem-resistant P. aeruginosa strains vs. carbapenems consumption (0.876 and 0.928, respectively). The best model describing the relation between combined-resistant P. aeruginosa strains and penicillins consumption during a given quarter incorporates both the consumption and the incidence of combined-resistant strains in the hospital department during the previous quarter (multiple R2 = 0.953, p = 0.017). The best model for explaining the carbapenem resistance of P. aeruginosa strains based on meropenem consumption during a given quarter proved to be the adjusted model which takes into consideration both previous consumption and incidence density of strains during the previous quarter (Multiple R2 = 0.921, p = 0.037). CONCLUSIONS: The cross-correlation coefficients and the fitted regression models provide additional evidence that resistance during the a given quarter depends not only on the consumption of antibacterial chemotherapeutic drugs in both that quarter and the previous one, but also on the incidence of resistant strains circulating during the previous quarter.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Bacteria/drug effects , Critical Care , Drug Resistance, Multiple, Bacterial/drug effects , Intensive Care Units , Anti-Bacterial Agents/administration & dosage , Bacteria/classification , Bacteria/pathogenicity , Carbapenems/therapeutic use , Drug Utilization/statistics & numerical data , Humans , Imipenem/therapeutic use , Meropenem , Microbial Sensitivity Tests , Penicillanic Acid/analogs & derivatives , Penicillanic Acid/therapeutic use , Phenotype , Piperacillin/therapeutic use , Piperacillin, Tazobactam Drug Combination , Prospective Studies , Pseudomonas Infections/microbiology , Pseudomonas aeruginosa/drug effects , Romania , Thienamycins/therapeutic use , beta-Lactamase Inhibitors/therapeutic use , beta-Lactams/therapeutic useABSTRACT
BACKGROUND: Rates of carbapenem-resistant Pseudomonas aeruginosa are increasing. Aggressive prevention strategies, including instituting antimicrobial stewardship programmes, are essential for combating antimicrobial resistance. OBJECTIVES: We conducted this study to compare the antimicrobial susceptibility pattern of P. aeruginosa before and after carbapenem restriction. METHODS: We conducted a two-phase retrospective study in an adult ICU. The first phase was from May until July 2016 (before carbapenem restriction), whereas the second phase was from September until November 2016 (while implementing carbapenem restriction). The antimicrobial susceptibility pattern of P. aeruginosa was reviewed in August and December 2016. The measure of carbapenem-resistant P. aeruginosa was the proportion of resistant isolates (percentage resistant). The measure of antibacterial consumption in the study phases was DDDs/1000 patient days. RESULTS: The overall carbapenem consumption decreased significantly in the second phase, from 28.44 to 11.67 DDDs/1000 patient days (P = 0.012). The resistance of P. aeruginosa to imipenem and meropenem decreased significantly from 76.0% to 38.5% (P = 0.019) and from 74.1% to 30.0% (P = 0.012), respectively. Susceptibility of P. aeruginosa to other antibacterials was not affected by carbapenem restriction. CONCLUSIONS: These data suggest that restricting carbapenems, even for a short duration, may be an effective strategy for managing the problem of carbapenem resistance in P. aeruginosa.
Subject(s)
Anti-Bacterial Agents/pharmacology , Antimicrobial Stewardship , Carbapenems/therapeutic use , Intensive Care Units , Pseudomonas Infections/drug therapy , Pseudomonas Infections/microbiology , Pseudomonas aeruginosa/drug effects , Adult , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Carbapenems/administration & dosage , Carbapenems/pharmacology , Drug Resistance, Bacterial , Drug Utilization , Humans , Imipenem/administration & dosage , Imipenem/pharmacology , Imipenem/therapeutic use , Meropenem , Microbial Sensitivity Tests , Pseudomonas aeruginosa/isolation & purification , Retrospective Studies , Thienamycins/administration & dosage , Thienamycins/pharmacology , Thienamycins/therapeutic useABSTRACT
We assessed the population pharmacokinetics of high-dose continuous-infusion (HDCI) meropenem in a cohort of patients with Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae (KPC-Kp) infections. Monte Carlo simulations were used to define the permissible HDCI meropenem regimens that could be safely considered for the treatment of KPC-Kp infections due to meropenem-resistant strains. Permissible doses were arbitrarily defined as those associated with a ≤10% to 15% likelihood of meropenem steady-state concentrations (Css) of >100 mg/liter. Probabilities of target attainment (PTA) of four incremental pharmacodynamic determinants for meropenem efficacy (100% T>1×MIC, 100% T>2×MIC, 100% T>3×MIC, and 100% T>4×MIC, where "T>MIC" represents the time during which the plasma concentration of this time-dependent antibacterial agent is maintained above the MIC for the pathogen) in relation to different classes of renal function were calculated. The cumulative fractions of response (CFR) for the permissible HDCI meropenem regimens were calculated against the MIC distribution of the KPC-Kp clinical isolates that were collected routinely at our University Hospital between 2013 and 2016 (n = 169). Ninety-seven meropenem Css were included in the analysis. The final model included creatinine clearance (CrCL) as a covariate and explained 94% of the population variability. Monte Carlo simulations based on licensed dosages of up to 6 g/day predicted an acceptable PTA (>80%) of 100% T>1×MIC against KPC-Kp with a meropenem MIC of ≤32 mg/liter in patients with a CrCL level of <130 ml/min. Dosages of 8 g/day were needed for achieving the same target in patients with CrCL at levels of 130 to 200 ml/min. In dealing with pathogens with a meropenem MIC of 64 mg/liter, HDCI regimens using meropenem at higher than licensed levels should be considered. In these cases, real-time therapeutic drug monitoring could be a useful adjunct for optimized care. The predicted CFR were >75% in all of the classes of renal function.
Subject(s)
Anti-Bacterial Agents , Bacteremia/drug therapy , Bacterial Proteins/metabolism , Klebsiella Infections/drug therapy , Klebsiella pneumoniae/drug effects , Thienamycins , beta-Lactamases/metabolism , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/blood , Anti-Bacterial Agents/pharmacokinetics , Anti-Bacterial Agents/pharmacology , Bacteremia/microbiology , Creatinine/blood , Drug Monitoring , Humans , Infusions, Intravenous , Klebsiella Infections/microbiology , Klebsiella pneumoniae/metabolism , Meropenem , Microbial Sensitivity Tests , Middle Aged , Monte Carlo Method , Retrospective Studies , Thienamycins/blood , Thienamycins/pharmacokinetics , Thienamycins/therapeutic useABSTRACT
Burkholderia sp. infections are extremely complex in cystic fibrosis (CF) patients, especially considering the lack of knowledge regarding its behavior, its relationship with prognosis, as well as its transmissibility and multidrug resistance features. This study evaluated the frequency of chronic infection by Burkholderia, using microbiological and clinical data. Ninety-eight patients with CF attended from July 2011 to April 2014 in a Brazilian reference hospital were included. Antimicrobial activity, molecular epidemiology, Shwachman score, body mass index, exacerbations, and lung function were analyzed. Nine patients had chronic colonization, and all of them showed preserved pulmonary function levels, body mass index, and Shwachman score. Meropenem was the most effective antibiotic; however, divergent results were shown by other studies. Cross-contamination may have occurred in only two unrelated patients of different ages, who were colonized by B. vietnamiensis, which does not occur frequently. Twelve new sequence types (STs) were identified and three STs have presented intercontinental distribution. None of the patients presented known epidemic strains. In conclusion, a relatively low number of patients with chronic colonization and suspected cross-infection were identified. Different from other studies that have found CF patients chronically colonized with Burkholderia sp. having a greater deterioration of lung function, more frequent antibiotic therapy, and increased mortality, in the current study, the patients showed good clinical outcomes and favorable options for antibiotics therapy. This study also updated the epidemiological database, which facilitates the multicentric collaborative analysis and assists in the control of global infection by these pathogens.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Burkholderia Infections/drug therapy , Burkholderia Infections/epidemiology , Burkholderia cepacia complex/isolation & purification , Cystic Fibrosis/microbiology , Adolescent , Adult , Brazil/epidemiology , Burkholderia Infections/complications , Burkholderia Infections/pathology , Burkholderia cepacia complex/classification , Burkholderia cepacia complex/genetics , Ceftazidime/therapeutic use , Child , Child, Preschool , Cross Infection , Cystic Fibrosis/complications , Electrophoresis, Gel, Pulsed-Field , Female , Hospitals , Humans , Infant , Lung/pathology , Male , Meropenem , Microbial Sensitivity Tests , Molecular Typing , Respiratory Function Tests , Thienamycins/therapeutic use , Treatment Outcome , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use , Young AdultABSTRACT
Escherichia coli Ec36 was recovered from a patient in Portugal after treatment with meropenem and colistin. Besides an IncF plasmid with Tn1441d-blaKPC-3, already reported in clinical strains in this country, E. coli Ec36 co-harbored an IncX4::mcr-1 gene. Results highlight emerging co-resistance to carbapenems and polymyxins after therapy with drugs from both classes.
Subject(s)
Escherichia coli Infections/epidemiology , Escherichia coli Infections/microbiology , Escherichia coli Proteins/genetics , Escherichia coli/drug effects , Escherichia coli/genetics , beta-Lactamases/genetics , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Colistin/pharmacology , Colistin/therapeutic use , Drug Resistance, Bacterial , Escherichia coli/classification , Escherichia coli Infections/drug therapy , Genotype , Humans , Meropenem , Microbial Sensitivity Tests , Portugal/epidemiology , Serogroup , Thienamycins/pharmacology , Thienamycins/therapeutic useABSTRACT
The recent escalation of occurrences of carbapenem-resistant Pseudomonas aeruginosa has been recognized globally and threatens to erode the widespread clinical utility of the carbapenem class of compounds for this prevalent health care-associated pathogen. Here, we compared the in vitro inhibitory activity of ceftazidime-avibactam and ceftolozane-tazobactam against 290 meropenem-nonsusceptible Pseudomonas aeruginosa nonduplicate clinical isolates from 34 U.S. hospitals using reference broth microdilution methods. Ceftazidime-avibactam and ceftolozane-tazobactam were active, with ceftolozane-tazobactam having significantly higher inhibitory activity than ceftazidime-avibactam. The heightened inhibitory activity of ceftolozane-tazobactam was sustained when the site of origin (respiratory, blood, or wound) and nonsusceptibility to other ß-lactam antimicrobials was considered. An extensive genotypic search for enzymatically driven ß-lactam resistance mechanisms revealed the exclusive presence of the VIM metallo-ß-lactamase among only 4% of the subset of isolates nonsusceptible to ceftazidime-avibactam, ceftolozane-tazobactam, or both. These findings suggest an important role for both ceftazidime-avibactam and ceftolozane-tazobactam against carbapenem-nonsusceptible Pseudomonas aeruginosa Further in vitro and in vivo studies are needed to better define the clinical utility of these novel therapies against the increasingly prevalent threat of multidrug-resistant Pseudomonas aeruginosa.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Azabicyclo Compounds/therapeutic use , Ceftazidime/therapeutic use , Cephalosporins/therapeutic use , Penicillanic Acid/analogs & derivatives , Pseudomonas Infections/drug therapy , Pseudomonas aeruginosa/drug effects , Thienamycins/therapeutic use , beta-Lactamase Inhibitors/therapeutic use , Catheter-Related Infections/drug therapy , Catheter-Related Infections/microbiology , Cross Infection/drug therapy , Cross Infection/microbiology , Drug Combinations , Humans , Meropenem , Microbial Sensitivity Tests , Penicillanic Acid/therapeutic use , Pseudomonas Infections/microbiology , Pseudomonas aeruginosa/isolation & purification , TazobactamABSTRACT
Infections caused by carbapenemase-producing Enterobacteriaceae (CPE) are becoming increasingly common worldwide. Although CPE infections can be fatal, few reports in the literature have described effective and successful treatments for infectious diseases caused by several types of IMP CPE, and, to our knowledge, no reports have described the successful treatment of IMP-6 CPE infections. We describe two patients who developed bacteremia caused by IMP-6 CPE after surgery for cancer who were successfully treated with amikacin plus high-dose prolonged-infusion meropenem. Both patients were treated over a 2-week period using amikacin 15 mg/kg at various intervals based on therapeutic drug monitoring and meropenem 2000 mg infused over 3 hours every 12 hours. The dosages of amikacin and meropenem were determined based on the creatinine clearance of each patient. Both patients were cured of their bacteremia and did not experience any antibiotic-related adverse effects. Based on the outcomes of these patients, it appears that amikacin plus high-dose prolonged-infusion meropenem may be safe and effective for the treatment of bacteremia caused by IMP-6 CPE.
Subject(s)
Amikacin/therapeutic use , Anti-Bacterial Agents/therapeutic use , Bacteremia/drug therapy , Carbapenem-Resistant Enterobacteriaceae/enzymology , Enterobacteriaceae Infections/drug therapy , Thienamycins/therapeutic use , Aged , Amikacin/administration & dosage , Anti-Bacterial Agents/administration & dosage , Bacteremia/microbiology , Bacterial Proteins/biosynthesis , Carbapenem-Resistant Enterobacteriaceae/drug effects , Drug Therapy, Combination , Enterobacteriaceae Infections/microbiology , Humans , Male , Meropenem , Microbial Sensitivity Tests , Thienamycins/administration & dosage , Treatment Outcome , beta-Lactamases/biosynthesisABSTRACT
Combination therapy including colistin and a carbapenem has been found to be associated with lower mortality in the treatment of bloodstream infections (BSI) due to KPC-producing Klebsiella pneumoniae when the isolates show a meropenem or imipenem MIC of <16 mg/liter. However, the optimal treatment of BSI caused by colistin- and high-level carbapenem-resistant KPC-producing K. pneumoniae is unknown. A prospective cohort study including episodes of bacteremia caused by colistin-resistant and high-level meropenem-resistant (MIC ≥ 64 mg/liter) KPC-producing K. pneumoniae diagnosed from July 2012 to February 2016 was performed. The impact of combination therapy on crude 30-day mortality was analyzed by Cox regression using a propensity score as a covariate to control for indication bias and in an inverse probability of treatment weighting (IPTW) cohort. The study sample comprised 104 patients, of which 32 (30.8%) received targeted monotherapy and 72 (69.2%) received targeted combination therapy; none of them received either colistin or a carbapenem. The 30-day crude mortality rate was 30.8% (43.8% in patients treated with monotherapy and 25% in patients receiving combination therapy). In the Cox regression analysis, 30-day mortality was independently associated with septic shock at BSI onset (hazard ratio [HR], 6.03; 95% confidence interval [CI], 1.65 to 21.9; P = 0.006) and admission to the critical care unit (HR, 2.87; 95% CI, 0.99 to 8.27; P = 0.05). Targeted combination therapy was associated with lower mortality only in patients with septic shock (HR, 0.14; 95% CI, 0.03 to 0.67; P = 0.01). These results were confirmed in the Cox regression analysis of the IPTW cohort. Combination therapy is associated with reduced mortality in patients with bacteremia due to colistin-resistant KPC-producing K. pneumoniae with high-level carbapenem resistance in patients with septic shock.